Cartesian Growth Corp II (REEUF)

Cartesian Growth Corporation II was created to serve a single purpose: raise capital and use it to acquire an operating business. Like most SPACs, it began as an empty shell. In May 2022, it raised roughly $230 million by listing on the Nasdaq. That trust account — the pool of money intended to pay for a business combination — was supposed to be deployed within two to three years to merge with or acquire a private company and take it public. That never happened. The clock has run out.

“Substantial doubt about the company’s ability to continue as a going concern” — a phrase that appears in any company’s filings when it is running out of money and has no clear path to revenue.

The company extended its deadline three times, each extension triggered by redemptions — existing shareholders cashing out rather than waiting for a deal. Each time, millions left the trust account. Today, after those redemptions, roughly $37 million remains in trust against a deadline of August 2026 to complete a transaction or dissolve. The company trades on the OTC Pink market, delisted from Nasdaq for failure to meet SPAC listing standards. REEUF represents the units (shares plus warrants), while REEWF and RENEF are shares and warrants separately.

The economics of dead money

The unit economics of a failed SPAC are stark: the sponsor and advisors collected their fees for running the IPO and managing the company; early shareholders who believed in a deal taking place saw their capital tied up for years at zero return; and everyone remaining holds shares in a company with no business and a shrinking pile of cash. The trust account was supposed to deploy into an acquisition; instead, it is leaking away in management fees and legal costs of organizing charter extensions. This is one of the cautionary tales of the SPAC boom — for every successful merger that brings a valued company public, several blank-check vehicles exhaust their capital and wind down.

Cartesian tried three times to find a target and failed. That is the most important fact. Investors who bought the IPO believed a deal would materialize; the market’s verdict was clear: no qualified target wanted these sponsors’ money, or no deal could be negotiated at acceptable terms. The resulting shell trades at a steep discount to book value — shareholders are paying less per dollar of cash remaining because that cash is locked away, redemptions are ongoing, and the only probable outcome is a liquidation at par or slightly lower.

Winding down

The company’s only option now is to complete a business combination by the deadline or redeem the remaining trust funds to shareholders and wind up. Neither path involves future revenue or growth. If a deal closes, whatever business is acquired becomes Cartesian’s subsidiary, and the dynamics shift entirely. If the company liquidates, SPAC shareholders receive their pro-rata share of trust capital, minus fees. The warrants — the right to buy shares at a fixed price — will almost certainly expire worthless.

For investors studying SPACs and blank-check companies, Cartesian is a data point: a $230 million blank check that found nothing to write. It illustrates why SPAC sponsors are now under scrutiny for their guarantees and conflict of interest — they are paid the same regardless of whether a deal materializes, so the incentive to complete a bad deal is real. It also explains the shift in later vintages toward stricter governance, sponsor skin-in-the-game, and greater disclosure of deal timelines.